Sparsentan Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Sparsentan Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
15
Registered trials
33
Result records
5
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Sparsentan can convert its Small molecule drug profile and AT1R x ETA biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Sparsentan (query alias: sparsentan) |
|---|---|
| Modality / target | Small molecule drug; AT1R x ETA; AT1R antagonists, ETA antagonists |
| Highest global status | Approved |
| Originator | Bristol Myers Squibb Co. |
| Active developers | Travere Therapeutics, Inc., Vifor France SASU, Renalys Pharma, Inc. |
The MCP disease footprint includes Glomerulosclerosis, Focal Segmental, Glomerulonephritis, IGA, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07219121 | Phase 4 | Active, not recruiting | 20 | Urinary protein/creatinine ratio (UPCR) |
| JPRN-jRCT2051240070 | Phase 3 | Not Recruiting | 30 | efficacy Change from baseline in urinary protein-to-creatinine ratio (UP/C) based on 24 hour urine samples at 36 weeks |
| NCT07224776 | Phase 1 | Not yet recruiting | 20 | Change in urine to protein creatinine ratio (UPCR) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A Multicentered, Single-group Phase 2, Exploratory, Open-label Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in the Treatment of Adult Participants With Immunoglobulin A Nephropathy (IgAN)
Phase 2; n=48; evaluation: not stated. Reported fields: -; -; Change in Urine Albumin-creatinine Ratio (UA/C) at Week 24(Least Squares Mean) = -55.78 percent change (95% Confidence Interval, -65.8 to -42.8)
New Era for FSGS Treatment
Not Applicable; n=620; evaluation: Positive. Reported fields: Optimally managed = Nephrologists rank FSGS among the top three rare kidney diseases with sizable unmet therapeutic needs. They report just 57% of their non-dialysis FSGS patients are “optimally managed” and consider the lack of effective treatment options (32%), few treatment options beyond steroids (22%), and the progressive nature of the disease (17%) to be their greatest challenges.
Baseline Characteristics and Treatment Satisfaction of Patients (Pts) Enrolled in IgAN Bridge: Interim Results from a Home-Reported Outcomes (HROs) Study
Not Applicable; n=22; evaluation: Positive. Reported fields: EQ-5D-5L = 0.8 point ( 0.2)
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Sparsentan addresses Glomerulosclerosis, Focal Segmental, Glomerulonephritis, IGA, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 5 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2025-10-24 | Roche's Chugai strikes $200M M&A deal to take over IgAN asset in several Asian countries | Approved | US$98.0M upfront; US$104.0M milestones; US$203.1M stated total |
| 2024-01-25 | Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations | Approved | US$120.0M milestones |
| 2021-09-15 | Vifor Pharma and Travere Therapeutics announce licensing agreement for the commercialization of sparsentan in Europe, Australia and New Zealand | Phase 2 | US$55.0M upfront; US$135.0M milestones; US$190.0M stated total |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Synthesis method for sparsentan intermediate”. The milestone feed surfaced a patent-application signal described as “Sparsentan for treating immunoglobulin a nephropathy (IGAN)”. The milestone feed surfaced a patent-application signal described as “Sparsentan for use in a method of treating IGA-mediated diseases”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
